Adrafinil

Adrafinil, sold under the brand name Olmifon, is a wakefulness-promoting medication that was formerly used in France to improve alertness, attention, wakefulness, and mood, particularly in the elderly.[2][3][4] It was also used off-label by individuals who wished to avoid fatigue, such as night workers or others who needed to stay awake and alert for long periods of time. Additionally, the medication has been used non-medically as a nootropic.[2]

Adrafinil
Clinical data
Trade namesOlmifon
Other namesCRL-40028
AHFS/Drugs.comInternational Drug Names
Routes of
administration		Oral
ATC code
Legal status
Legal status
  • AU: S4 (Prescription only)
  • US: Not FDA approved, unscheduled
Pharmacokinetic data
Bioavailability80%
Metabolism75% (liver)
MetabolitesModafinil
Elimination half-life1 hour (T1/2 is 12–15 hours for modafinil)[1]
ExcretionKidney
Identifiers
IUPAC name
  • (±)-2-Benzhydrylsulfinylethanehydroxamic acid
CAS Number
PubChem CID
DrugBank
ChemSpider
UNII
KEGG
ChEMBL
CompTox Dashboard (EPA)
ECHA InfoCard100.058.440
Chemical and physical data
FormulaC15H15NO3S
Molar mass289.35 g·mol−1
3D model (JSmol)
SMILES
  • O=S(C(c1ccccc1)c2ccccc2)CC(=O)NO
InChI
  • InChI=1S/C15H15NO3S/c17-14(16-18)11-20(19)15(12-7-3-1-4-8-12)13-9-5-2-6-10-13/h1-10,15,18H,11H2,(H,16,17) Y
  • Key:CGNMLOKEMNBUAI-UHFFFAOYSA-N Y
 NY (what is this?)  (verify)

Adrafinil is a prodrug; it is primarily metabolized in vivo to modafinil, resulting in very similar pharmacological effects.[2] Unlike modafinil, however, it takes time for the metabolite to accumulate to active levels in the bloodstream. Effects usually are apparent within 45–60 minutes when taken orally on an empty stomach.

Adrafinil was marketed in France until September 2011 when it was voluntarily discontinued due to an unfavorable risk–benefit ratio.[3]

Medical uses

Adrafinil is a wakefulness-promoting agent and was used to promote alertness, attention, wakefulness, and mood.[2] It was particularly used in the elderly.[2]

Available forms

Adrafinil was available in the form of 300 mg oral tablets.[5][3]

Side effects

There is a case report of two patients that adrafinil may increase interest in sex.[2]

A case report of adrafinil-induced orofacial dyskinesia exists.[6][7] Reports of this side effect also exist for modafinil.[6]

Pharmacology

Pharmacodynamics

Because α1-adrenergic receptor antagonists were found to block effects of adrafinil and modafinil in animals, "most investigators assume[d] that adrafinil and modafinil both serve as α1-adrenergic receptor agonists."[2] However, adrafinil and modafinil have not been found to bind to the α1-adrenergic receptor and they lack peripheral sympathomimetic side effects associated with activation of this receptor;[8] hence, the evidence in support of this hypothesis is weak, and other mechanisms are probable.[2] Modafinil was subsequently screened at a variety of targets in 2009 and was found to act as a weak, atypical blocker of the dopamine transporter (and hence as a dopamine reuptake inhibitor), and this action may explain some or all of its pharmacological effects.[9][10][11] Relative to adrafinil, modafinil possesses greater specificity in its action, lacking or having a reduced incidence of many of the common side effects of the former (including stomach pain, skin irritation, anxiety, and elevated liver enzymes with prolonged use).[12][13]

Pharmacokinetics

In addition to modafinil, adrafinil also produces modafinil acid (CRL-40467) and modafinil sulfone (CRL-41056) as metabolites, which form from metabolic modification of modafinil.

Chemistry

Analogues of adrafinil include modafinil, armodafinil, CRL-40,940, CRL-40,941, and fluorenol.

History

Adrafinil was discovered in 1974 by two chemists working for the French pharmaceutical company Laboratoires Lafon who were screening compounds in search of analgesics.[14] Pharmacological studies of adrafinil instead revealed psychostimulant-like effects such as hyperactivity and wakefulness in animals.[14] The substance was first tested in humans, specifically for the treatment of narcolepsy, in 1977–1978.[14] Introduced by Lafon (now Cephalon), it reached the market in France in 1984,[3] and for the treatment of narcolepsy in 1985.[14][15]

In 1976, two years after the discovery of adrafinil, modafinil, its active metabolite, was discovered.[14] Modafinil appeared to be more potent than adrafinil in animal studies, and was selected for further clinical development, with both adrafinil and modafinil eventually reaching the market.[14] Modafinil was first approved in France in 1994, and then in the United States in 1998.[15] Lafon was acquired by Cephalon in 2001.[16] As of September 2011, Cephalon has discontinued Olmifon, its adrafinil product, while modafinil continues to be marketed.[3]

Society and culture

Names

Adrafinil is the generic name of the drug and its INN and DCF.[4] It is also known by its brand name Olmifon and its developmental code name CRL-40028.[4]

Athletic doping

Adrafinil and its active metabolite modafinil were added to the list of substances prohibited for athletic competition according to World Anti-Doping Agency in 2004.[17]

New Zealand

In 2005 a Medical Classification Committee in New Zealand recommended to MEDSAFE NZ that adrafinil be classified as a prescription medicine due to risks of it being used as a party drug. At that time adrafinil was not scheduled in New Zealand.[18]

Research

In a clinical trial with the tricyclic antidepressant clomipramine and placebo as comparators, adrafinil showed efficacy in the treatment of depression.[2] In contrast to clomipramine however, adrafinil was well-tolerated, and showed greater improvement in psychomotor retardation in comparison.[2] The authors concluded that further investigation of the potential antidepressant effects of adrafinil were warranted.[2]

References
  1. Robertson P, Hellriegel ET (2003). "Clinical pharmacokinetic profile of modafinil". Clin Pharmacokinet. 42 (2): 123–37. doi:10.2165/00003088-200342020-00002. PMID 12537513. S2CID 1266677.
  2. Milgram, Norton (1999). "Adrafinil: A Novel Vigilance Promoting Agent". CNS Drug Reviews. 5 (3): 193–212. doi:10.1111/j.1527-3458.1999.tb00100.x.
  3. AFSSAPS (2011). "Point d'information sur les dossiers discutés en commission d'AMM Séance du jeudi 1er décembre 2011 - Communiqué". Archived from the original on 13 September 2017.
  4. Index Nominum 2000: International Drug Directory. Taylor & Francis. January 2000. pp. 20–. ISBN 978-3-88763-075-1.
  5. A. Kleemann; J. Engel; B. Kutscher; D. Reichert; Axel Kleemann; Jürgen Engel; Bernhard Kutscher; Dietmar Reichert (14 May 2014). Pharmaceutical Substances, 5th Edition, 2009: Syntheses, Patents and Applications of the most relevant APIs (5 ed.). Georg Thieme Verlag. ISBN 978-3-13-179525-0.
  6. Jeffrey K Aronson (31 December 2012). Side Effects of Drugs Annual: A worldwide yearly survey of new data in adverse drug reactions. Newnes. pp. 6–. ISBN 978-0-444-59503-4.
  7. Thobois S, Xie J, Mollion H, Benatru I, Broussolle E (2004). "Adrafinil-induced orofacial dyskinesia". Mov. Disord. 19 (8): 965–6. doi:10.1002/mds.20154. PMID 15300665. S2CID 31816404.
  8. Simon P, Chermat R, Puech AJ (1983). "Pharmacological evidence of the stimulation of central alpha-adrenergic receptors". Prog. Neuropsychopharmacol. Biol. Psychiatry. 7 (2–3): 183–6. doi:10.1016/0278-5846(83)90105-7. PMID 6310690. S2CID 45147850.
  9. Zolkowska D, Jain R, Rothman RB, Partilla JS, Roth BL, Setola V, Prisinzano TE, Baumann MH (May 2009). "Evidence for the involvement of dopamine transporters in behavioral stimulant effects of modafinil". The Journal of Pharmacology and Experimental Therapeutics. 329 (2): 738–46. doi:10.1124/jpet.108.146142. PMC 2672878. PMID 19197004.
  10. Reith ME, Blough BE, Hong WC, Jones KT, Schmitt KC, Baumann MH, Partilla JS, Rothman RB, Katz JL (Feb 2015). "Behavioral, biological, and chemical perspectives on atypical agents targeting the dopamine transporter". Drug and Alcohol Dependence. 147: 1–19. doi:10.1016/j.drugalcdep.2014.12.005. PMC 4297708. PMID 25548026.
  11. Quisenberry AJ, Baker LE (Dec 2015). "Dopaminergic mediation of the discriminative stimulus functions of modafinil in rats". Psychopharmacology. 232 (24): 4411–9. doi:10.1007/s00213-015-4065-0. PMID 26374456. S2CID 15519396.
  12. Ballas, Christos A; Deborah Kim; Claudia F Baldassano; Nicholas Hoeh (July 2002). "Modafinil: past, present and future". Expert Review of Neurotherapeutics. 2 (4): 449–57. doi:10.1586/14737175.2.4.449. PMID 19810941. S2CID 32939239.
  13. Alan F. Schatzberg; Charles B. Nemeroff (2009). The American Psychiatric Publishing Textbook of Psychopharmacology. American Psychiatric Pub. pp. 850–. ISBN 978-1-58562-309-9.
  14. Antonio Guglietta (28 November 2014). Drug Treatment of Sleep Disorders. Springer. pp. 212–. ISBN 978-3-319-11514-6.
  15. Jie Jack Li; Douglas S. Johnson (27 March 2013). Modern Drug Synthesis. John Wiley & Sons. pp. 2–. ISBN 978-1-118-70124-9.
  16. url=https://www.bloomberg.com/research/stocks/private/snapshot.asp?privcapId=1366624
  17. World Anti-Doping Agency - 2007 Prohibited List Archived 2009-04-10 at the Wayback Machine
  18. MCC Minutes Out of Session Meeting. Medsafe.govt.nz (2013-05-23). Retrieved on 2013-12-18.
This article is issued from Wikipedia. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.